# Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia

> **NCT00914888** · PHASE3 · WITHDRAWN · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Community Acquired Bacterial Pneumonia
- Complicated Intra-Abdominal Infection

## Interventions

- **DRUG:** Tigecycline
- **DRUG:** Tigecycline
- **DRUG:** cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside
- **DRUG:** CAP: Ceftriaxone, plus if applicable oral clarithromycin

## Key facts

- **NCT ID:** NCT00914888
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-01
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00914888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00914888, "Study Evaluating Tigecycline Versus Ceftriaxone In Complicated Intra-Abdominal Infections & Community Acquired Pneumonia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00914888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*